CN103998053B - 通过抑制il-4和/或il-13与其各自的受体结合来预防或治疗某些障碍的方法 - Google Patents
通过抑制il-4和/或il-13与其各自的受体结合来预防或治疗某些障碍的方法 Download PDFInfo
- Publication number
- CN103998053B CN103998053B CN201280061754.7A CN201280061754A CN103998053B CN 103998053 B CN103998053 B CN 103998053B CN 201280061754 A CN201280061754 A CN 201280061754A CN 103998053 B CN103998053 B CN 103998053B
- Authority
- CN
- China
- Prior art keywords
- lipocalin mutein
- purposes according
- lipocalin
- albumen
- obstacle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (40)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811146540.5A CN109432402B (zh) | 2011-12-13 | 2012-12-12 | 通过抑制il-4和/或il-13与其各自的受体结合来预防或治疗某些障碍的方法 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161570018P | 2011-12-13 | 2011-12-13 | |
US61/570,018 | 2011-12-13 | ||
PCT/EP2012/075146 WO2013087660A1 (en) | 2011-12-13 | 2012-12-12 | Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811146540.5A Division CN109432402B (zh) | 2011-12-13 | 2012-12-12 | 通过抑制il-4和/或il-13与其各自的受体结合来预防或治疗某些障碍的方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
CN103998053A CN103998053A (zh) | 2014-08-20 |
CN103998053B true CN103998053B (zh) | 2018-11-02 |
CN103998053B9 CN103998053B9 (zh) | 2020-07-21 |
Family
ID=47552959
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201280061754.7A Active CN103998053B9 (zh) | 2011-12-13 | 2012-12-12 | 通过抑制il-4和/或il-13与其各自的受体结合来预防或治疗某些障碍的方法 |
CN201811146540.5A Active CN109432402B (zh) | 2011-12-13 | 2012-12-12 | 通过抑制il-4和/或il-13与其各自的受体结合来预防或治疗某些障碍的方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811146540.5A Active CN109432402B (zh) | 2011-12-13 | 2012-12-12 | 通过抑制il-4和/或il-13与其各自的受体结合来预防或治疗某些障碍的方法 |
Country Status (13)
Country | Link |
---|---|
US (6) | US9572863B2 (zh) |
EP (3) | EP3842058B1 (zh) |
JP (5) | JP6163162B2 (zh) |
CN (2) | CN103998053B9 (zh) |
AU (1) | AU2012350660B2 (zh) |
CA (1) | CA2858962C (zh) |
DK (2) | DK3453400T3 (zh) |
ES (2) | ES2710384T3 (zh) |
HU (2) | HUE054342T2 (zh) |
PL (2) | PL3453400T3 (zh) |
SG (2) | SG11201402992SA (zh) |
TR (1) | TR201901826T4 (zh) |
WO (1) | WO2013087660A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102417217B1 (ko) | 2016-06-08 | 2022-07-05 | 쑤저우 커넥트 바이오파마슈티컬즈, 엘티디. | 인터루킨 4 수용체에 결합하는 항체 |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105949301B (zh) * | 2010-06-08 | 2020-03-27 | 皮里斯制药有限公司 | 结合IL-4受体α的泪脂质运载蛋白突变蛋白 |
DK3453400T3 (da) | 2011-12-13 | 2021-04-06 | Pieris Pharmaceuticals Gmbh | Fremgangsmåder til forebyggelse eller behandling af visse forstyrrelser ved inhibering af binding af il-4 og/eller il-13 til deres respektive receptorer |
BR112016027024A2 (pt) * | 2014-05-22 | 2017-10-31 | Pieris Pharmaceuticals Gmbh | polipeptídeos de ligação específica e seus usos |
EA201890198A1 (ru) | 2015-07-15 | 2018-07-31 | ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ | Новые белки, специфичные в отношении lag-3 |
EP3571219A1 (en) | 2017-01-18 | 2019-11-27 | Pieris Pharmaceuticals GmbH | Lipocalin muteins with binding affinity for lag-3 |
WO2018195388A1 (en) | 2017-04-21 | 2018-10-25 | Kindred Biosciences, Inc. | Il4/il13 receptor molecule for veterinary use |
CN111494625B (zh) * | 2018-12-25 | 2022-06-21 | 江苏荃信生物医药股份有限公司 | 用于治疗il-4和/或il-13介导的信号转导相关的疾病的药物组合物 |
EP3946417A1 (en) | 2019-03-29 | 2022-02-09 | Pieris Pharmaceuticals GmbH | Inhaled administration of lipocalin muteins |
WO2020200960A1 (en) | 2019-03-29 | 2020-10-08 | Astrazeneca Ab | Lipocalin mutein for treatment of asthma |
WO2022129629A1 (en) | 2020-12-18 | 2022-06-23 | Astrazeneca Ab | Lipocalin mutein dry powder formulation for treatment of asthma |
CN115414467B (zh) * | 2022-10-14 | 2023-06-06 | 中国人民解放军陆军军医大学第二附属医院 | 载脂蛋白d在制备治疗脑出血药物中的用途 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008015239A2 (en) * | 2006-08-01 | 2008-02-07 | Pieris Ag | Muteins of tear lipocalin and methods for obtaining the same |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンaの製造方法 |
FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
DE4425255A1 (de) | 1994-07-16 | 1996-01-18 | Asta Medica Ag | Formulierung zur inhalativen Applikation |
US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
US6446467B1 (en) | 1997-07-29 | 2002-09-10 | Physical Optics Corporation | Monolithic glass light shaping diffuser and method for its production |
DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
TR200003635T2 (tr) | 1998-06-08 | 2001-04-20 | F.Hoffmann-La Roche Ag | Peg-IFN-ALFA ve ribavirinin kronik hepatit C tedavisinde kullanılması. |
US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
DE19926068C1 (de) | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteine des Bilin-Bindungsproteins |
DE10043509A1 (de) | 2000-09-01 | 2002-03-14 | Asta Medica Ag | Feste Peptidzubereitungen für die Inhalation und deren Herstellung |
EP1377306A1 (en) | 2001-03-09 | 2004-01-07 | Dyax Corp. | Serum albumin binding moieties |
WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
EP1430136A1 (en) | 2001-09-27 | 2004-06-23 | Pieris ProteoLab AG | Muteins of apolipoprotein d |
AU2003233583A1 (en) * | 2002-05-24 | 2003-12-12 | Agennix Incorporated | Oral lactoferrin in the treatment of respiratory disorders |
WO2005019255A1 (en) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
AU2003264100A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of a bilin-binding protein with affinity for a given target |
RU2389796C2 (ru) | 2003-08-29 | 2010-05-20 | Аэровэнс, Инк. | Модифицированный антагонист рецептора il-4 и предназначенный для его получения очищенный полинуклеотид |
EP2899277A1 (en) | 2004-11-26 | 2015-07-29 | Pieris AG | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
EP1929073A4 (en) | 2005-09-27 | 2010-03-10 | Amunix Inc | PROTEIN MEDICAMENT AND ITS USE |
EP1996613B1 (en) | 2006-03-20 | 2014-04-30 | Technische Universität München | Muteins of tear lipocalin with affinity for the t-cell coreceptor cd4 |
CN101784280A (zh) * | 2007-07-11 | 2010-07-21 | 艾罗文斯公司 | 药物多肽干粉气溶胶制剂及制备方法 |
CN105949301B (zh) | 2010-06-08 | 2020-03-27 | 皮里斯制药有限公司 | 结合IL-4受体α的泪脂质运载蛋白突变蛋白 |
DK3453400T3 (da) | 2011-12-13 | 2021-04-06 | Pieris Pharmaceuticals Gmbh | Fremgangsmåder til forebyggelse eller behandling af visse forstyrrelser ved inhibering af binding af il-4 og/eller il-13 til deres respektive receptorer |
-
2012
- 2012-12-12 DK DK18197286.0T patent/DK3453400T3/da active
- 2012-12-12 PL PL18197286T patent/PL3453400T3/pl unknown
- 2012-12-12 JP JP2014546471A patent/JP6163162B2/ja active Active
- 2012-12-12 SG SG11201402992SA patent/SG11201402992SA/en unknown
- 2012-12-12 WO PCT/EP2012/075146 patent/WO2013087660A1/en active Application Filing
- 2012-12-12 CA CA2858962A patent/CA2858962C/en active Active
- 2012-12-12 ES ES12813295T patent/ES2710384T3/es active Active
- 2012-12-12 SG SG10201604566QA patent/SG10201604566QA/en unknown
- 2012-12-12 US US14/364,449 patent/US9572863B2/en active Active
- 2012-12-12 CN CN201280061754.7A patent/CN103998053B9/zh active Active
- 2012-12-12 EP EP21152253.7A patent/EP3842058B1/en active Active
- 2012-12-12 AU AU2012350660A patent/AU2012350660B2/en active Active
- 2012-12-12 EP EP12813295.8A patent/EP2790719B1/en active Active
- 2012-12-12 ES ES18197286T patent/ES2863410T3/es active Active
- 2012-12-12 DK DK12813295.8T patent/DK2790719T3/en active
- 2012-12-12 PL PL12813295T patent/PL2790719T3/pl unknown
- 2012-12-12 CN CN201811146540.5A patent/CN109432402B/zh active Active
- 2012-12-12 TR TR2019/01826T patent/TR201901826T4/tr unknown
- 2012-12-12 EP EP18197286.0A patent/EP3453400B1/en active Active
- 2012-12-12 HU HUE18197286A patent/HUE054342T2/hu unknown
- 2012-12-12 HU HUE12813295A patent/HUE042720T2/hu unknown
-
2016
- 2016-12-02 US US15/367,680 patent/US10016483B2/en active Active
-
2017
- 2017-03-30 JP JP2017067615A patent/JP6725447B2/ja active Active
-
2018
- 2018-06-07 US US16/002,704 patent/US10398754B2/en active Active
-
2019
- 2019-03-28 JP JP2019062186A patent/JP6889201B2/ja active Active
- 2019-07-16 US US16/513,636 patent/US10857202B2/en active Active
-
2020
- 2020-05-27 JP JP2020092168A patent/JP2020164532A/ja active Pending
- 2020-11-05 US US17/090,571 patent/US11382951B2/en active Active
-
2022
- 2022-03-25 JP JP2022049676A patent/JP7441589B2/ja active Active
- 2022-06-14 US US17/839,635 patent/US20230021168A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008015239A2 (en) * | 2006-08-01 | 2008-02-07 | Pieris Ag | Muteins of tear lipocalin and methods for obtaining the same |
Non-Patent Citations (2)
Title |
---|
Next generation therapeutics for the treatment of respiratory diseases-dscovery and characterization of an inhalable highly potent and specific anti-IL-4Ra small protein antagonist;HOHLBAUM A.M.等;《INFLAMMATION RESEARCH》;20110630;第60卷(第1期);82-83 * |
Non-immunoglobulin based protein scaffolds;John Lfblom等;《CURRNET OPINION IN BIOTECHNOLOGY》;20110602;第22卷(第6期);843-848 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102417217B1 (ko) | 2016-06-08 | 2022-07-05 | 쑤저우 커넥트 바이오파마슈티컬즈, 엘티디. | 인터루킨 4 수용체에 결합하는 항체 |
KR102502988B1 (ko) | 2016-06-08 | 2023-02-23 | 쑤저우 커넥트 바이오파마슈티컬즈, 엘티디. | 인터루킨 4 수용체에 결합하는 항체 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103998053B (zh) | 通过抑制il-4和/或il-13与其各自的受体结合来预防或治疗某些障碍的方法 | |
Fornasa et al. | Dichotomy of short and long thymic stromal lymphopoietin isoforms in inflammatory disorders of the bowel and skin | |
Ingram et al. | IL‐13 and IL‐1β promote lung fibroblast growth through coordinated up‐regulation of PDGF‐AA and PDGF‐Rα | |
ES2651268T3 (es) | Composiciones que contienen alfa-1-antitripsina y métodos para su uso | |
CN103796667A (zh) | 用补体抑制剂治疗慢性障碍的方法 | |
Mishra et al. | Resistin-like molecule-β is an allergen-induced cytokine with inflammatory and remodeling activity in the murine lung | |
CN106913865A (zh) | 使用白细胞介素‑10治疗疾病和病症的方法 | |
CN105658232A (zh) | 使用白细胞介素-10治疗疾病和病症的方法 | |
JP2012514586A (ja) | Il−21およびil−21変異体に基づく抗体欠乏性疾患を治療するための手段および方法 | |
CN101027079A (zh) | 嵌合蛋白 | |
US20220401515A1 (en) | Application of non-igf1r-binding substance in prevention and/or treatment of inflammatory diseases | |
TW202317645A (zh) | 一種融合蛋白及其醫藥用途 | |
Hashemzadeh | Mohammad Sadegh Hashemzadeh1, Hadi Esmaeili Gouvarchin Ghaleh2, Mozafar Mohammadi3, Yaser Yousefpoor4, Ehsan Rezaei5, Gholamhossein Alishiri6 | |
Hsia | The Role of Caveolin-1 and Surfactant Protein A as Regulators of Airway Hyperreactivity and Inflammation Following Innate Immune Challenges |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: Freising, Germany - Stephen Weah Applicant after: Pires Pharmaceutical Co. Ltd. Address before: Freising, Germany - Stephen Weah Applicant before: Pieris AG |
|
CB02 | Change of applicant information | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20180402 Address after: Freising, Germany - Stephen Weah Applicant after: Pires Pharmaceutical Co. Ltd. Applicant after: BRISTOL-MYERS SQUIBB COMPANY Address before: Freising, Germany - Stephen Weah Applicant before: Pires Pharmaceutical Co. Ltd. |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CI03 | Correction of invention patent |
Correction item: Claims|Description Correct: Claims 1-40 submitted on May 29, 2020|Paragraphs 1-133 of the specification submitted on May 29, 2020 False: Claims 1-40 submitted on May 24, 2018|13-1 / 2014 Number: 44-02 Page: ?? Volume: 34 |
|
CI03 | Correction of invention patent |